|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111.88 USD | +2.22% |
|
+0.06% | +5.52% |
| 06:48pm | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
| 06:03pm | Merck, CEPI Collaborate on More Affordable Ebola Vaccine | MT |
| Capitalization | 272B 232B 216B 202B 375B 24,883B 402B 2,474B 979B 11,760B 1,019B 998B 42,958B | P/E ratio 2025 * |
14x | P/E ratio 2026 * | 19.7x |
|---|---|---|---|---|---|
| Enterprise value | 298B 255B 236B 222B 411B 27,289B 441B 2,714B 1,074B 12,897B 1,117B 1,094B 47,111B | EV / Sales 2025 * |
4.6x | EV / Sales 2026 * | 4.28x |
| Free-Float |
70.67% | Yield 2025 * |
2.95% | Yield 2026 * | 3.01% |
Last Transcript: Merck & Co., Inc.
| 1 day | +2.24% | ||
| 1 week | +0.06% | ||
| Current month | +5.52% | ||
| 1 month | +6.07% | ||
| 3 months | +26.77% | ||
| 6 months | +40.05% | ||
| Current year | +5.52% |
| 1 week | 106.93 |  | 111.58 |
| 1 month | 100.4 | | 112.9 |
| Current year | 104.43 | | 112.9 |
| 1 year | 73.31 | | 112.9 |
| 3 years | 73.31 | | 134.63 |
| 5 years | 70.89 | | 134.63 |
| 10 years | 47.97 | | 134.63 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 59 | 30/06/2021 |
| Director of Finance/CFO | 57 | 31/03/2021 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 57 | 31/07/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 65 | 26/11/2007 |
Patricia Russo
BRD | Director/Board Member | 73 | 31/08/1995 |
Robert Davis
CHM | Chairman | 59 | 30/11/2022 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -2.99% | 14.34% | 253 M€ | |
| -0.59% | 5.61% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.22% | +0.06% | +15.41% | +1.09% | 272B | |
| +3.18% | -0.38% | +44.03% | +212.44% | 932B | |
| -1.04% | -1.50% | +45.31% | +27.90% | 526B | |
| +0.72% | -3.21% | +24.43% | +44.58% | 378B | |
| -0.38% | +0.17% | +27.57% | +16.67% | 374B | |
| -1.35% | -7.03% | +20.68% | +20.84% | 282B | |
| +0.07% | -1.48% | +27.95% | +33.84% | 278B | |
| -4.02% | -1.16% | -34.82% | -22.56% | 272B | |
| +3.26% | +3.07% | +23.38% | +29.92% | 178B | |
| +3.35% | +2.89% | +37.32% | +53.37% | 154B | |
| Average | +0.52% | +0.20% | +23.13% | +41.81% | 364.58B | |
| Weighted average by Cap. | +0.69% | -0.30% | +28.16% | +70.99% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 64.84B 55.43B 51.46B 48.26B 89.53B 5,939B 95.87B 591B 234B 2,807B 243B 238B 10,253B | 67.76B 57.93B 53.78B 50.44B 93.57B 6,206B 100B 617B 244B 2,933B 254B 249B 10,715B |
| Net income | 20.1B 17.19B 15.95B 14.96B 27.76B 1,841B 29.72B 183B 72.45B 870B 75.38B 73.83B 3,179B | 14.05B 12.01B 11.15B 10.46B 19.4B 1,287B 20.77B 128B 50.64B 608B 52.68B 51.6B 2,221B |
| Net Debt | 26.26B 22.46B 20.85B 19.55B 36.27B 2,406B 38.84B 239B 94.67B 1,137B 98.49B 96.48B 4,153B | 18.55B 15.86B 14.72B 13.81B 25.61B 1,699B 27.42B 169B 66.85B 803B 69.55B 68.13B 2,933B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/01/26 | 111.12 $ | +1.53% | 5,951,595 |
| 20/01/26 | 109.45 $ | +0.57% | 15,241,138 |
| 16/01/26 | 108.83 $ | -1.93% | 14,852,069 |
| 15/01/26 | 110.97 $ | -0.04% | 11,775,844 |
| 14/01/26 | 111.01 $ | +2.54% | 11,964,625 |
Delayed Quote Nyse, January 21, 2026 at 07:16 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition